论文部分内容阅读
目的探讨辛伐他汀联合通心络胶囊治疗冠心病的治疗及安全性。方法回顾性分析我院自2011年1月至2013年1月收治的冠心病患者76例,分成治疗组42例和对照组34例。对照组给予辛伐他汀。治疗组给予辛伐他汀和通心络胶囊。比较治疗后两组总体临床疗效。血清甘油醋(TG)血清总胆固醇(TG)低密度脂蛋白(LDL-C)高密度脂蛋白(HDL-C)以及安全性。结果治疗组与对照组临床总有效率分别为82.4%(36/42).59.5%(21/34)两组比较(χ~2=5.74.P<0.05)治疗组与对照组治疗后比较在TG,LDL-C水平比较(P<0.05).HDL-C水平比较(P>0.05).治疗组出现胃肠道不良反应率8.8%,对照组为14.3%,两组比较(χ~2=0.43.P<0.05)结论:辛伐他汀与通心络胶囊联合治疗CHD可以提高临床有效率。降低血脂水平。且安全性较好。值得临床应用。
Objective To investigate the treatment and safety of simvastatin combined with Tongxinluo capsule in the treatment of coronary heart disease. Methods A retrospective analysis of 76 cases of coronary heart disease admitted to our hospital from January 2011 to January 2013 were divided into treatment group (n = 42) and control group (n = 34). The control group was given simvastatin. The treatment group was given simvastatin and Tongxinluo capsule. Compare the overall clinical efficacy of two groups after treatment. Serum triglyceride (TG) serum total cholesterol (TG) low density lipoprotein (HDL-C) high density lipoprotein (HDL-C) and safety. Results The total clinical effective rates in the treatment group and the control group were 82.4% (36/42) respectively. Compared with the control group (59.5%, 21/34) TG and LDL-C levels (P <0.05) .HDL-C levels were significantly higher in treatment group than in control group (8.8% vs 14.3%, χ ~ 2 = 0.43.P <0.05) Conclusion: The combination of simvastatin and Tongxinluo capsule can improve the clinical efficiency. Reduce blood lipid levels. And safety is better. Worth clinical application.